These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 15375769

  • 1. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders.
    Kvasnicka HM, Thiele J.
    Histol Histopathol; 2004 Oct; 19(4):1245-60. PubMed ID: 15375769
    [Abstract] [Full Text] [Related]

  • 2. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.
    Lekovic D, Gotic M, Skoda R, Beleslin-Cokic B, Milic N, Mitrovic-Ajtic O, Nienhold R, Sefer D, Suboticki T, Buac M, Markovic D, Diklic M, Cokic VP.
    Ann Hematol; 2017 Mar; 96(3):393-404. PubMed ID: 27924369
    [Abstract] [Full Text] [Related]

  • 3. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A.
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [Abstract] [Full Text] [Related]

  • 4. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
    Panteli K, Zagorianakou N, Bai M, Katsaraki A, Agnantis NJ, Bourantas K.
    Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, Arcaini L, Pascutto C, Castello A, Cazzola M, Magrini U, Lazzarino M.
    Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inability of immunomorphometric assessment of angiogenesis to distinguish primary versus secondary myelofibrosis.
    Sharma P, Pati HP, Mishra PC, Dinda AK, Gupta R, Sharma A, Jacob TG.
    Anal Quant Cytol Histol; 2011 Aug; 33(4):236-44. PubMed ID: 21980629
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A, Kriener S, Engels K, Staib P, Griesshammer M, Waller CF, Ottmann OG, Hansmann ML.
    Histol Histopathol; 2004 Oct; 19(4):1277-88. PubMed ID: 15375771
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
    Thiele J, Kvasnicka HM, Vardiman J.
    Best Pract Res Clin Haematol; 2006 Oct; 19(3):413-37. PubMed ID: 16781481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.